JP2017527578A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527578A5
JP2017527578A5 JP2017513450A JP2017513450A JP2017527578A5 JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5 JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
irritable bowel
bowel syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527578A (ja
JP6538154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/056905 external-priority patent/WO2016038552A1/en
Publication of JP2017527578A publication Critical patent/JP2017527578A/ja
Publication of JP2017527578A5 publication Critical patent/JP2017527578A5/ja
Application granted granted Critical
Publication of JP6538154B2 publication Critical patent/JP6538154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513450A 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体 Expired - Fee Related JP6538154B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/086197 2014-09-10
CN2014086197 2014-09-10
CNPCT/CN2015/086995 2015-08-14
CN2015086995 2015-08-14
PCT/IB2015/056905 WO2016038552A1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019102776A Division JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Publications (3)

Publication Number Publication Date
JP2017527578A JP2017527578A (ja) 2017-09-21
JP2017527578A5 true JP2017527578A5 (OSRAM) 2018-10-25
JP6538154B2 JP6538154B2 (ja) 2019-07-03

Family

ID=54186249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513450A Expired - Fee Related JP6538154B2 (ja) 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Country Status (36)

Country Link
US (4) US9918974B2 (OSRAM)
EP (2) EP3517526B1 (OSRAM)
JP (2) JP6538154B2 (OSRAM)
KR (1) KR20170045350A (OSRAM)
CN (1) CN107074768B (OSRAM)
AU (1) AU2015313841B2 (OSRAM)
BR (1) BR112017004900A2 (OSRAM)
CA (1) CA2960768A1 (OSRAM)
CL (1) CL2017000588A1 (OSRAM)
CO (1) CO2017002273A2 (OSRAM)
CR (1) CR20170093A (OSRAM)
CY (1) CY1121661T1 (OSRAM)
DK (1) DK3191450T3 (OSRAM)
DO (1) DOP2017000059A (OSRAM)
EA (1) EA033544B1 (OSRAM)
ES (2) ES2725704T3 (OSRAM)
HR (1) HRP20190815T1 (OSRAM)
HU (1) HUE044604T2 (OSRAM)
IL (1) IL250908B (OSRAM)
LT (1) LT3191450T (OSRAM)
MA (1) MA40581A (OSRAM)
ME (1) ME03432B (OSRAM)
MX (1) MX373863B (OSRAM)
MY (1) MY181913A (OSRAM)
PE (1) PE20170705A1 (OSRAM)
PH (1) PH12017500425A1 (OSRAM)
PL (1) PL3191450T3 (OSRAM)
PT (1) PT3191450T (OSRAM)
RS (1) RS58813B1 (OSRAM)
SG (1) SG11201701694QA (OSRAM)
SI (1) SI3191450T1 (OSRAM)
SM (1) SMT201900304T1 (OSRAM)
TW (1) TWI683807B (OSRAM)
UA (1) UA122213C2 (OSRAM)
UY (1) UY36293A (OSRAM)
WO (1) WO2016038552A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
UA122213C2 (uk) * 2014-09-10 2020-10-12 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret)
UA123084C2 (uk) 2014-09-10 2021-02-17 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret)
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519672A (ja) 2017-05-15 2020-07-02 ブループリント メディシンズ コーポレイション RET阻害剤とmTORC1阻害剤との組合せ及び異常なRET活性によって媒介されるがんを処置するためのその使用
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
FI3773589T3 (fi) 2018-04-03 2024-02-01 Blueprint Medicines Corp Ret-estäjä käytettäväksi ret-muunnoksen sisältävän syövän hoidossa
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
US12448366B2 (en) 2020-05-29 2025-10-21 Rigel Pharmaceuticals, Inc. Solid forms of pralsetinib
WO2022017524A1 (zh) * 2020-07-23 2022-01-27 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
KR20250052364A (ko) 2022-08-24 2025-04-18 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
DK1047418T3 (da) * 1997-12-22 2005-11-21 Bayer Pharmaceuticals Corp Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
HUP0203542A3 (en) 1999-08-12 2003-07-28 Upjohn Co 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 4−置換アリール−5−ヒドロキシイソキノリノン誘導体
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JP5124285B2 (ja) * 2004-12-28 2013-01-23 キネックス ファーマシューティカルズ, エルエルシー 細胞増殖性障害を処置する組成物および方法
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
WO2008002676A2 (en) 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
JP5568304B2 (ja) * 2006-09-15 2014-08-06 タイロジェネクス,インコーポレイテッド キナーゼ阻害剤化合物
CA2666116A1 (en) * 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
SI2848610T1 (en) * 2006-11-15 2018-02-28 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
EP2970191B1 (en) 2013-03-15 2016-12-21 GlaxoSmithKline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
UA123084C2 (uk) 2014-09-10 2021-02-17 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret)
UA122213C2 (uk) 2014-09-10 2020-10-12 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки як інгібітори кінази, реаранжованої під час трансфекції (ret)

Similar Documents

Publication Publication Date Title
JP2017527578A5 (OSRAM)
JP2017526711A5 (OSRAM)
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
JP2013543896A5 (OSRAM)
JP2017528503A5 (OSRAM)
JP2013527202A5 (OSRAM)
JP2017504635A5 (OSRAM)
JP2017535550A5 (OSRAM)
JP2016503010A5 (OSRAM)
JP2015145426A5 (OSRAM)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2014525470A5 (OSRAM)
JP2015516434A5 (OSRAM)
JP2013526482A5 (OSRAM)
JP2015524472A5 (OSRAM)
JP2017528507A5 (OSRAM)
FI3699181T3 (fi) Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
NZ627750A (en) Carbamate compounds and of making and using same
JP2020510661A5 (OSRAM)
JP2009529541A5 (OSRAM)
JP2014511892A5 (OSRAM)
JP2009541216A5 (OSRAM)
JP2014062126A5 (OSRAM)
JP2021530565A5 (OSRAM)
JP2014502979A5 (OSRAM)